Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhao Hai-Lu

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 6, 2025
[Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering]Zhao Hai Lu, Tomoko Matsui, Audrey Au, et al.
The Journal of Biological Chemistry|December 15, 2012
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implicationsBo Tan, Debra A Young, Zhao-Hai Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer ImmunotherapyDavid A Schaer, Sandaruwan Geeganage, Nelusha Amaladas, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 6, 2025
[Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering]Zhao Hai Lu, Tomoko Matsui, Audrey Au, et al.
The Journal of Biological Chemistry|December 15, 2012
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implicationsBo Tan, Debra A Young, Zhao-Hai Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer ImmunotherapyDavid A Schaer, Sandaruwan Geeganage, Nelusha Amaladas, et al.
Pageof 1